240 related articles for article (PubMed ID: 18220506)
1. Heparin, heparan sulfate and heparanase in cancer: remedy for metastasis?
Li JP
Anticancer Agents Med Chem; 2008 Jan; 8(1):64-76. PubMed ID: 18220506
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species.
Bar-Ner M; Eldor A; Wasserman L; Matzner Y; Cohen IR; Fuks Z; Vlodavsky I
Blood; 1987 Aug; 70(2):551-7. PubMed ID: 2955820
[TBL] [Abstract][Full Text] [Related]
3. Molecular properties and involvement of heparanase in cancer progression and mammary gland morphogenesis.
Zcharia E; Metzger S; Chajek-Shaul T; Friedmann Y; Pappo O; Aviv A; Elkin M; Pecker I; Peretz T; Vlodavsky I
J Mammary Gland Biol Neoplasia; 2001 Jul; 6(3):311-22. PubMed ID: 11547900
[TBL] [Abstract][Full Text] [Related]
4. [Human heparanase: roles in invasion and metastasis of cancer].
Gohji K; Katsuoka Y; Okamoto M; Kamidono S; Kitazawa S; Toyoshima M; Dong J; Nakajima M
Hinyokika Kiyo; 2000 Oct; 46(10):757-62. PubMed ID: 11215206
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase.
Levy-Adam F; Abboud-Jarrous G; Guerrini M; Beccati D; Vlodavsky I; Ilan N
J Biol Chem; 2005 May; 280(21):20457-66. PubMed ID: 15760902
[TBL] [Abstract][Full Text] [Related]
6. The impact of heparanese and heparin on cancer metastasis and angiogenesis.
Vlodavsky I; Abboud-Jarrous G; Elkin M; Naggi A; Casu B; Sasisekharan R; Ilan N
Pathophysiol Haemost Thromb; 2006; 35(1-2):116-27. PubMed ID: 16855356
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
Vlodavsky I; Mohsen M; Lider O; Svahn CM; Ekre HP; Vigoda M; Ishai-Michaeli R; Peretz T
Invasion Metastasis; 1994-1995; 14(1-6):290-302. PubMed ID: 7657522
[TBL] [Abstract][Full Text] [Related]
8. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin.
Lewis EJ; Xu X
Diabetes Care; 2008 Feb; 31 Suppl 2():S202-7. PubMed ID: 18227486
[TBL] [Abstract][Full Text] [Related]
9. [The great Scandinavian Jahre Prize 1993. What is the function of heparan sulfate?].
Lindahl U
Nord Med; 1994; 109(1):4-8. PubMed ID: 8028997
[TBL] [Abstract][Full Text] [Related]
10. Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression.
Gerber U; Hoß SG; Shteingauz A; Jüngel E; Jakubzig B; Ilan N; Blaheta R; Schlesinger M; Vlodavsky I; Bendas G
Semin Thromb Hemost; 2015 Mar; 41(2):244-54. PubMed ID: 25682080
[TBL] [Abstract][Full Text] [Related]
11. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.
Sanderson RD; Elkin M; Rapraeger AC; Ilan N; Vlodavsky I
FEBS J; 2017 Jan; 284(1):42-55. PubMed ID: 27758044
[TBL] [Abstract][Full Text] [Related]
12. [Research advancement on heparanase in tumor metastasis].
Li ZH; Yang SM
Ai Zheng; 2005 Sep; 24(9):1156-60. PubMed ID: 16159446
[TBL] [Abstract][Full Text] [Related]
13. Murine macrophage heparanase: inhibition and comparison with metastatic tumor cells.
Savion N; Disatnik MH; Nevo Z
J Cell Physiol; 1987 Jan; 130(1):77-84. PubMed ID: 3805131
[TBL] [Abstract][Full Text] [Related]
14. Properties and function of heparanase in cancer metastasis and angiogenesis.
Vlodavsky I; Goldshmidt O
Haemostasis; 2001; 31 Suppl 1():60-3. PubMed ID: 11990483
[TBL] [Abstract][Full Text] [Related]
15. Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes.
Matzner Y; Bar-Ner M; Yahalom J; Ishai-Michaeli R; Fuks Z; Vlodavsky I
J Clin Invest; 1985 Oct; 76(4):1306-13. PubMed ID: 2997275
[TBL] [Abstract][Full Text] [Related]
16. Multi-faceted substrate specificity of heparanase.
Peterson SB; Liu J
Matrix Biol; 2013 Jun; 32(5):223-7. PubMed ID: 23499529
[TBL] [Abstract][Full Text] [Related]
17. Molecular properties and involvement of heparanase in cancer progression and normal development.
Vlodavsky I; Goldshmidt O; Zcharia E; Metzger S; Chajek-Shaul T; Atzmon R; Guatta-Rangini Z; Friedmann Y
Biochimie; 2001 Aug; 83(8):831-9. PubMed ID: 11530216
[TBL] [Abstract][Full Text] [Related]
18. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties.
Lapierre F; Holme K; Lam L; Tressler RJ; Storm N; Wee J; Stack RJ; Castellot J; Tyrrell DJ
Glycobiology; 1996 Apr; 6(3):355-66. PubMed ID: 8724143
[TBL] [Abstract][Full Text] [Related]
19. Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin.
Nasser NJ; Sarig G; Brenner B; Nevo E; Goldshmidt O; Zcharia E; Li JP; Vlodavsky I
J Thromb Haemost; 2006 Mar; 4(3):560-5. PubMed ID: 16460439
[TBL] [Abstract][Full Text] [Related]
20. Heparan sulfate chains contribute to the anticoagulant milieu in malignant pleural effusion.
Hardak E; Peled E; Crispel Y; Ghanem S; Attias J; Asayag K; Kogan I; Nadir Y
Thorax; 2020 Feb; 75(2):143-152. PubMed ID: 31892546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
